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The aim of this paper was to outline the costs, options and scope for a company in the South African 
Contract Cleaning Industry to implement effective HIV/AIDS workplace programmes. Case study 
methodology is used. A cost model which estimates the costs associated with replacing an AIDS 
affected employee over time is used. The costs are not significant to the company as they are able to 
transfer most of the cost of illness onto their employees. There are significant risks for the company 
however, to the existence and costs associated with insured employee benefits into the future. This 
company has minimised their risks to the negative impacts of HIV/AIDS by adopting several cost saving 
strategies. This is however, to the detriment of their employees. 
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INTRODUCTION 
 
The aim of this paper was to outline the costs, options 
and scope for a case study company in the South African 
Contract Cleaning Industry (CCI) to implement effective 
HIV/AIDS workplace programmes. The results from 
HIV/AIDS cost impact assessments conducted at the 
case study company in late 2006 are presented. The 
options for action by the company are essentially a 
summary of the key results which describe objectively the 
situation that the industry confronts. The implications for 
planning interventions in the company and industry are 
then discussed.   
  
 
Background 
 
The industry employs approximately 80,000 people in 
labour intensive work. The majority of employees are 
unskilled workers (cleaners) who earn relatively low 
wages of R1,500 per month and have very limited health 
and pension benefits. The rate of exchange in late 2006 
was  US$1   =   7.5  South   African   Rands.   There   are  
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approximately 340 companies in the industry. The 
employer organisation, the National Contract Cleaning 
Association (NCCA), represents over 240 of the 
companies. In contrast, less than 30% of employees 
belong to trade unions and several unions operate in this 
industry. The Bargaining Council for Contract Cleaning 
Industry (BCCCI) in KwaZulu-Natal was created to main-
tain fair and equitable industrial relations and conditions 
of the employment for the Industry. It is made up of an 
equal number of employer and employee (union) 
members. The Bargaining Council covers approximately 
11,000 employees (15%) in the industry.  
The South African Business Coalition on HIV/AIDS 
(SABCOHA) was formed in 2000 in an effort to 
encourage the private sector to acknowledge the real 
threat of the epidemic to businesses and to respond 
appropriately.   
 
 
The case study company 
 
A recent sero-prevalence survey of the company was the 
basis for conducting an HIV/AIDS impact assessment 
study of the company with the aim of gaining insights into 
the general threat of the epidemic to the company. The 
case study company in the sector is a medium-sized  one 
  
 
 
with 500 employees. 
Company F is located in Durban and has 498 
employees. The majority (443) of these employees are 
carers/cleaners who work mainly in aged care facilities 
engaged in bathing and cleaning elderly people. Other 
cleaners work in charitable and corporate organisations. 
There are also 30 registered nurses employed on a full 
time basis, as well as 10 supervisors and 15 head office 
administrative staff.  
At the time of the study, there were 419 ‘black’ women 
employees, 15 ‘black’ men and 9 ‘coloured’ women. 75% 
of the employees were aged 35 years or older and had 
been working for the company on a long term basis. 
The employee profile is typical of contract cleaning 
companies: employees are mainly women (the female to 
male ratio is 80:20); all employees are ‘black’ in terms of 
South Africa’s current population categorisation model; 
the majority are middle-aged and have long periods of 
service for the company.  
The average wage for cleaners is R14,000 per 
employee per annum. Regulated casual wage rates are 
R9 per hour. Wages are also typical for the industry, but 
on the low side: R80/day for casual employees and 
R1,490 per month for full time employees. Other 
conditions of employment fall within the industry-level 
agreements. Full time employees are entitled to four 
weeks paid annual leave in December. They all belong to 
the BCCCI Provident Fund, administered by Negotiated 
Benefits Consultants (NBC). Employees contribute 6% of 
their salary and the company contributes another 6% to 
the Fund. Benefits in the case of death include one year’s 
salary and R3,000 to assist with funeral costs. There is 
no medical aid scheme or employer contribution to health 
insurance and, we believe, no cleaning employee has 
medical aid cover.  
The company does not have a medical aid scheme or 
employer contribution to health insurance packages for 
any of its cleaning and carer staff, but the management 
reported that a few (non cleaning) employees pay for 
medical aid coverage. Sick leave benefits include two-
days salary for temporary absence due to illness as long 
as the employee has a doctor’s certificate. Employees 
and the company both contribute 1% each of salary to 
the Unemployment Insurance Fund (UIF).  Income 
insurance is available to employees at a cost of R5 per 
month.  
The HIV sero-prevalence study was conducted by Dr. 
Mark Colvin from the Centre for AIDS Development, 
Research and Evaluation (CADRE). This received 
approval from the University of KwaZulu-Natal Medical 
Ethics Committee. 
The total number of people that participated by 
providing usable specimens was 147 or 30% of the total 
workforce. A total of 45 people or 31% of those tested 
(45/147 x 100) were infected with HIV. Two men out of 12 
(16%) and 43 out of 135 (32%) of women were infected. 
The data shows that the highest levels of  infection  are 
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in the 30 to 40 year age group band, but that infections 
occur in all ages. 
 
 
AIDS projection model (APM) 
 
The demographic impact of the HIV/AIDS epidemic on 
the workforce over the period 2000 - 2015 was computed 
using the AIDS Projection Model (APM) (Matthews, 
2007). The HIV sero-prevalence data is an anonymous 
list of employees with the following characteristics, 
categorised as: 
 
i. Job band - managerial, skilled, labourer 
ii. Race - black, ACW (Asian, Coloured, White) 
iii. Gender – male, female 
iv. Ages 20-34, 35-49, 50-64. 
 
 
METHODS 
 
The financial cost of HIV/AIDS to companies  
 
Figure 1 illustrates the different types of costs that companies can 
incur.  
The underlying issue here is the way costs of HIV infection are 
delayed. Notably, for an individual, the virus can incubate for 3 - 5 
years before he or she begins to suffer HIV-related illnesses and, if 
unable to get adequate treatment, suffers increasing bouts of more 
severe and varied opportunistic illnesses and, ultimately, death 5-
10 years after infection.  
Likewise, the cost to any organisation arising from an employee 
becoming infected is delayed. Figure 2 presents a schematic 
picture of the dynamic.  
However, in reality an organisation is incurring costs arising from 
employees infected several years ago while the costs of new infec-
tions arise only in the future (Rosen et al., 2003; 2004; Bureau of 
Economic Research, 2004 and 2005; SABCOHA, 2004). 
Furthermore, as the assessment above shows, it must be noted 
that costs for an organisation do not inevitably increase over time. 
Any assessment of cost impacts has to take into account both the 
dynamics of epidemics generally (that is, infection rates eventually 
taper off) and the development of responses (that is, gradual 
expansion of prevention and anti-retroviral and other treatment 
programmes in South Africa over the next few years). 
Bowler (2007) reported the results of a descriptive study of 
HIV/AIDS in manufacturing workplaces in Nelson Mandela 
metropolis area. The levels of HIV infection, illness and death were 
established. Although, there had been an impact on costs, these 
had been contained without a negative impact on profitability. She 
found that every workplace had engaged in some aspects of 
HIV/AIDS management and had complied with legal requirements. 
Further, that the management of every workplace had responded to 
the specific issue of HIV, although programme usage was limited. It 
was found that HIV programmes were management driven but 
there was limited involvement from unions. 
 
 
RESULTS 
 
Information on the recruitment and employment practices 
of this company indicated patterns and trends in the way 
HIV/AIDS is affecting the company.  These  patterns  and  
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Figure 1. Progression of Cases, Costs, and Liability (Rosen et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Direct (out of pocket) costs Indirect (productivity) costs 
From one employee 
with HIV/AIDS 
(individual costs) 
 Benefits payments 
 Medical care 
 Recruitment and training of 
a replacement employee 
 Reduced on-the-job productivity 
 Increased leave and absenteeism 
 Supervisor’s time 
 Vacancy until replacement is hired
 Poorer performance while new 
employee learns the job 
From many employees 
with HIV/AIDS 
(organisational costs) 
 Benefits premiums 
 Accidents 
 Legal costs 
 Senior management time 
 Production disruptions 
 Loss of workforce morale, 
cohesion, and experience 
 Deteriorating labor relations 
Total Workforce-Related Costs of HIV/AIDS 
 
 
 
Figure 2.  Costs of HIV/AIDS to Companies ( Rosen et al., 2000). 
 
 
 
trends, though suggestive rather than definitive, provide 
important factors that need to be considered in the 
planning of any industry or company-level interventions.     
The findings for the case study company were:  
 
1. The company will entail an average cost of R9,007 for 
each individual employee who becomes infected with 
HIV. 
2. That cost is 63.2% of average annual salary of an 
individual. 
3. The bulk of the cost is incurred in the provident fund 
payment (R8,515) 
4. The incidence of new HIV infection will decrease 
(projections up to 2015). 
5. The number of employees dying or retiring due to 
disability to work will increase threefold (from approx 7  to 
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Table 1. Direct and indirect costs of a new HIV infection 
(Case Study Company) (R). 
 
Type of costs Amount (R) 
Direct  
Provident Fund 8515 
Medical Care 0 
Recruitment 59 
Training 148 
  
Indirect  
Sick Leave 285 
  
Total 9007 
 
 
 
Table 2. Total cost of HIV/AIDS in the year incurred, 1999-2015 (Case Study Company) (R). 
 
Year Total in year incurred Present value 
2000 20,172 177,814 
2001 33,624 166,193 
2002 53,088 142,602 
2003 79,495 119,023 
2004 113,103 100,965 
2005 153,481 87,969 
2006 199,519 77,898 
2007 249,133 69,247 
2008 299,815 61,338 
2009 348,072 54,099 
2010 390,977 47,566 
2011 425,810 41,867 
2012 450,959 36,927 
2013 465,782 32,812 
2014 470,788 28,998 
2015 467,543 26,134 
 
 
 
22 individuals per year).   
6. The overall financial cost of HIV/AIDS to the company 
decreases over the next ten years.  
 
Table 1 summarises the direct and indirect costs to the 
company for each employee who becomes infected.  
The overall cost of HIV/AIDS actually decreases over 
time. Although, the cost increases from R11,439 in 1999 
to R467,543 in 2005, the value or worth of those sums in 
relation to the current value shows that: 
 
1) The cost to the company was R167,558 in 1999; in 
2006, it was R77,898; and in 2015, it will be R26,134.  
2) The current cost R61,338 amounts to approximately 
1.0% of the annual salary bill of R6.28 million, but that 
proportion decreases to approximately 0.7% of the salary 
bill in 2010 and thereafter (up to 2015) it remains 
relatively flat at 0.4% of the salary bill.  
Table 2 presents a summary of the calculations.  
Adequate human resource information to undertake the 
detailed analysis was available from the case study 
company.  
It will not be possible to do the same for many other 
companies in the industry because many do not have 
adequate data on employees in their human resource 
records.  
The findings from this company may or may not be 
indicative of a pattern in other companies in the industry.     
It is a slim base from which to assess the broader 
implications.   Accordingly,   the   following   assessment 
needs to keep that caveat in mind. 
 
 
DISCUSSION 
 
The key conclusion of the cost impact assessment is  that 
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the company has not and will not likely incur a large 
financial burden as a result of HIV infections amongst its 
workforce. The cost of R9,007 per individual, it must be 
remembered, is actually spread out over time. The total 
costs of all infections actually decrease in real terms. This 
conclusion supports the anecdotal reports from managers 
and supervisors at other companies that they had not 
perceived any significant financial effects of HIV/AIDS 
(Fraser et al., 2002; Chao et al., 2007; Rosen et al., 
2007). 
However, it must be noted that the conclusion ignores 
hidden costs that the study could not determine; for 
instance, lower productivity of workers if sick yet present 
at work (presenteeism). It is these costs that are possibly 
significant. There is the possibility that there will be more 
instances of workers taking time off to obtain treatment at 
public health facilities which could reduce work 
productivity generally (for example, in time spent by 
supervisors to re-arrange teams and greater workloads 
on staff present) in addition to potential increases in 
direct costs such as sick leave payments.   
However, even if that scenario is likely, for many 
companies one must also acknowledge the evidence 
from the company that their labour practices minimise the 
threat of HIV/AIDS raising their indirect costs. On the one 
hand, general practice in the industry seems to be for 
companies to each have a pool of casual workers to draw 
upon; thereby enabling them to offset occasional 
absences of full time staff. On the other hand, the 
demographic characteristics of the workforce in the case 
study company, if common throughout the industry, is a 
de facto means to reduce the financial costs of HIV/AIDS. 
The workforce in the company is primarily women over 
the age of 35. This means, from a statistical perspective, 
that a large proportion (if not majority in most companies 
in the industry) fall within a category of the population that 
is less at risk of infection than others (for example, 15 - 
20 year-old youth; 20 - 40 year-old men and women).   
 
 
Implications 
 
The data presented do not indicate that a significant 
financial threat to the company exists from the observed 
level of HIV/AIDS in their workforce. This situation may or 
may not be applicable across the industry. However, it 
does indicate that there is a possible significant threat to 
the BCCCI provident fund. The bulk of the costs that 
arise from HIV infection of an individual worker occur in 
the provident fund contributions to support death and 
disability retirement benefit payment to an employee’s 
estate. This cost is insignificant, however, compared to 
the actual costs borne by the fund itself. Simply put, the 
threat is that there will be increasing rate and number of 
payments from the fund. An additional threat is that the 
fund might not be able to absorb this increase in 
expenditure if there is a marked increase  in  the  number  
 
 
 
 
of members who have been employed for relatively short 
periods of time by companies. In other words, the general 
sustainability of the fund depends on long term 
contributions to the fund on the part of members.  
The limited evidence from the study suggests, 
however, that there is as yet no discernable threat to the 
fund. On the one hand, evidence of labour turnover at the 
company indicates that HIV/AIDS is not a principal cause 
for attrition. In the case study company, the average 
annual turnover of staff is 20% but only 6% were 
attributed to illness and/or death due to HIV/AIDS. That 
proportion will increase but as the projections also 
indicate, the rate will level off. A survey of 80 small and 
medium sized businesses in Gauteng and KwaZulu-Natal 
indicated an average of 13% staff attrition annually but 
HIV/AIDS-related attrition accounted for 1.4% only of that 
attrition (Connelly and Rosen, 2004). Accordingly, the 
question is whether the levelled percentage imposes 
more than simply a small yet notable burden on the fund, 
but also reduces the funds overall financial footing. This 
seems unlikely given the established practice in the 
South African insurance industry to raise marginally 
contribution levels to cover that burden (and also to 
reduce benefits). Furthermore, the employment practices 
of companies indirectly mitigate the threat. If it is, or 
becomes, common practice for companies to employ 
middle-aged and older women primarily, then the threat 
of HIV/AIDS to the fund would not increase. Benefit 
payments for other causes of death could, of course, 
increase. 
 
 
Managing the risk to insured benefits 
 
Many companies purchase death, disability, and medical 
benefits from outside insurance providers. The employer 
and the employee share the cost of the premiums for 
these benefits, and the insurance provider assumes the 
risk that the employee will make a claim for payment.  
As more employees succumb to AIDS, claims for 
medical care and death and disability benefits will 
increase, and the cost of purchasing these benefits will 
inevitably also rise. To avoid losing money, the providers 
must charge enough in premiums to cover their claims, 
administrative costs, and profits. If a particular employer’s 
claims are increasing, it is very likely that the premiums 
charged by the insurer will increase as well.   
There are various strategies that have been imple-
mented by employers to manage the impact of rising 
benefit costs as a result of HIV/AIDS in provident and 
pension funds (Stevens et al., 2005; Rosen et al., 2007; 
Dickinson et al., 2005). The appropriate strategy must be 
in line with the objectives of the fund for benefit provision. 
The following are possible strategies that could be put in 
place:   
 
1. Capping the  contribution  rate  to  risk  benefits  for  all  
  
 
 
categories of members. This change would cause a 
reduction in benefits over time should the contribution 
level remain the same. 
2. Increase employer contributions to maintain current 
benefit levels. This is only a short-term solution and may 
well not be affordable in the longer term.  
3. Set up a Risk Reserve to mitigate future cost increases 
and volatility. This will tie up some of the company’s 
capital and has equity implications, since one generation 
will be subsidising another. 
4. Restrict access to benefits. Strategies designed to limit 
or exclude access to benefits of people who are HIV 
positive include pre-benefit testing, exclusions and 
waiting periods. Before any strategy in this category is to 
be implemented consideration needs to be given to 
various legal and moral issues.  
5. Implementation of an HIV/AIDS management program. 
All the options above manage the symptoms and effects 
of the epidemic and not the epidemic itself. This can be 
done by implementing a holistic HIV/AIDS management 
program, including full treatment and medication. In the 
long run this could lead to not only savings on the cost of 
risk benefits, but also other direct and indirect 
employment-related costs.  
 
 
The potential for industry interventions 
 
The case study company has minimized the threat of 
HIV/AIDS to their operations. On the other hand, their 
workforces are very vulnerable in that the costs of the 
epidemic have been defrayed onto a population that has 
very limited financial and social security. This is the 
situation broadly applicable in the industry and is the 
starting point for any consideration of where and how it 
might intervene constructively (SABCOHA, 2002).  
The findings do not provide substantive reasons for 
companies themselves to support development of 
HIV/AIDS workplace programmes. Reports of managers 
during the study affirm the general view that most 
companies are motivated to provide HIV/AIDS services 
only when they see a negative financial effect on the 
business from AIDS or became aware of employees who 
were sick. A survey by Connelly and Rosen (2004) as 
well as those of SABCOHA (2002), Global Business 
Coalition on HIV/AIDS (2006) and George (2003) reveal 
little appreciation in the private sector of the benefits of 
pro-active prevention, treatment, care and support 
interventions. The projected financial costs of future HIV 
infections in the workforce of the case study company 
provide the sums which, hypothetically, the company 
should invest annually in a reserve fund to cover the 
future costs to the company. Equally, these are sums that 
the company could invest in HIV prevention activities to 
reduce future costs but there is no means to predict the 
effectiveness of such an investment.  
Irrespective of whether the assessment of the case 
study company is representative of the industry, there is  
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certainly no incentive for companies to support promotion 
of workplace ART programmes or even worker member-
ship of medical aid schemes. The 2008 annual cost of a 
currently standard treatment regime for an AIDS patient, 
on the protocol recommended by the World Health 
Organisation, is R3,200 (1st line treatment) and R6,400 
(2nd line treatment) (National Department of Health, 
2008). These sums amount to 20-40% of the average 
cleaner’s annual wages. To demand support from com-
panies to cover these costs is unrealistic. Direct support 
would inevitably pose questions about why HIV/AIDS 
specifically and not other life-threatening and/or terminal 
diseases deserves investment. The cost of providing 
health insurance would be prohibitive for workers and 
increase substantively the overall labour costs for a 
company working in a context that is highly competitive 
and geared to reducing those costs. Contract cleaning 
companies exist because of efforts by their clients to 
reduce not only wages but the benefit costs of labour. 
Nonetheless, the findings show that there is a need for 
intervention as the workforce is particularly vulnerable. 
HIV/AIDS is having an impact on the industry but the 
costs are largely hidden and they are mainly borne by the 
workers who are poorly paid and have minimal welfare 
assistance and health insurance.  
The results and analysis presented here do not present 
a strong business case for firms to undertake ameliora-
tion activities around HIV/AIDS. However, there is a 
strong case for industry level initiatives especially with 
regards to managing HIV/AIDS in the workforces of small 
and medium sized businesses. To enable this, BCCCI, 
SABCOHA and the Services SETA should facilitate an 
industry wide plan to assist companies. This would 
involve at a minimum the development of policies and the 
design of programs on prevention (condom distribution, 
peer education) and linking with the government’s 
national anti-retroviral treatment program to enable their 
AIDS ill workers to access treatment.   
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